HIV Treatment as Prevention: Considerations in the Design, Conduct, and Analysis of Cluster Randomized Controlled Trials of Combination HIV Prevention


The rigorous evaluation of the impact of combination HIV prevention packages at the population level will be critical for the future of HIV prevention. In this review, we discuss important considerations for the design and interpretation of cluster randomized controlled trials (C-RCTs) of combination prevention interventions. We focus on three large C-RCTs that will start soon and are designed to test the hypothesis that combination prevention packages, including expanded access to antiretroviral therapy, can substantially reduce HIV incidence. Using a general framework to integrate mathematical modelling analysis into the design, conduct, and analysis of C-RCTs will complement traditional statistical analyses and strengthen the evaluation of the interventions. Importantly, even with combination interventions, it may be challenging to substantially reduce HIV incidence over the 2- to 3-y duration of a C-RCT, unless interventions are scaled up rapidly and key populations are reached. Thus, we propose the innovative use of mathematical modelling to conduct interim analyses, when interim HIV incidence data are not available, to allow the ongoing trials to be modified or adapted to reduce the likelihood of inconclusive outcomes. The preplanned, interactive use of mathematical models during C-RCTs will also provide a valuable opportunity to validate and refine model projections.


Vyšlo v časopise: HIV Treatment as Prevention: Considerations in the Design, Conduct, and Analysis of Cluster Randomized Controlled Trials of Combination HIV Prevention. PLoS Med 9(7): e32767. doi:10.1371/journal.pmed.1001250
Kategorie: Review
prolekare.web.journal.doi_sk: 10.1371/journal.pmed.1001250

Souhrn

The rigorous evaluation of the impact of combination HIV prevention packages at the population level will be critical for the future of HIV prevention. In this review, we discuss important considerations for the design and interpretation of cluster randomized controlled trials (C-RCTs) of combination prevention interventions. We focus on three large C-RCTs that will start soon and are designed to test the hypothesis that combination prevention packages, including expanded access to antiretroviral therapy, can substantially reduce HIV incidence. Using a general framework to integrate mathematical modelling analysis into the design, conduct, and analysis of C-RCTs will complement traditional statistical analyses and strengthen the evaluation of the interventions. Importantly, even with combination interventions, it may be challenging to substantially reduce HIV incidence over the 2- to 3-y duration of a C-RCT, unless interventions are scaled up rapidly and key populations are reached. Thus, we propose the innovative use of mathematical modelling to conduct interim analyses, when interim HIV incidence data are not available, to allow the ongoing trials to be modified or adapted to reduce the likelihood of inconclusive outcomes. The preplanned, interactive use of mathematical models during C-RCTs will also provide a valuable opportunity to validate and refine model projections.


Zdroje

1. Joint United Nations Programme on HIV/AIDS 2011 World AIDS day report. How to get to zero: faster. smarter. better. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf. Accessed 25 November 2011

2. Alliance for Microbicide Development 2009 HIV/STI prevention research and development: October 2009 pipeline update of microbicide and PrEP candidates. Available: http://www.microbicide.org/uploads/3/1/2/1/3121935/microbicide_pipeline_update_1_oct_2009.pdf. Accessed 31 December 2011

3. US President's Emergency Plan for AIDS Relief 2011 August Guidance for the prevention of sexually transmitted HIV infections. Available: http://www.pepfar.gov/documents/organization/171303.pdf. Accessed 2 January 2012

4. SchwartlanderBStoverJHallettTAtunRAvilaC 2011 Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 377 2031 2041

5. BoilyMCAbu-RaddadLDesaiKMasseBSelfS 2008 Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. Lancet Infect Dis 8 200 207

6. BoilyMCDesaiKMasseBGumelA 2008 Incremental role of male circumcision on a generalised HIV epidemic through its protective effect against other sexually transmitted infections: from efficacy to effectiveness to population-level impact. Sex Transm Infect 84 ii28 ii34

7. BrissonMEdmundsWJ 2003 Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 23 76 82

8. DonnerAKlarN 2000 Design and analysis of cluster randomization trials in health research New York Oxford University Press

9. US Department of State (2011 September 14) PEPFAR announces largest study of combination HIV prevention. Available: http://www.state.gov/r/pa/prs/ps/2011/09/172389.htm. Accessed 2 January 2012

10. GranichRGuptaSSutharABSmythCHoosD 2011 Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 9 446 469

11. HIV Modelling Consortium 2011 The potential impact of treatment on HIV incidence. Available: https://docs.google.com/viewer?a=v&pid=explorer&chrome=true&srcid=0B3AFjYLL-il3MGNhYjVkN2UtZmIwMy00ZWE4LWI4MDEtNTQ4NDVmNDNmYjRm&hl=en_US. Accessed 2 January 2012

12. PadianNSMcCoySIBalkusJEWasserheitJN 2010 Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 24 621 635

13. BoilyMCLowndesCMVickermanPKumaranayakeLBlanchardJ 2007 Evaluating large-scale HIV prevention interventions: study design for an integrated mathematical modelling approach. Sex Transm Infect 83 582 589

14. KorenrompELVan VlietCGrosskurthHGavyoleAVan der PloegCP 2000 Model-based evaluation of single-round mass treatment of sexually transmitted diseases for HIV control in a rural African population. AIDS 14 573 593

15. BoilyMCLowndesCMAlaryM 2000 Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda. AIDS 14 2583 2592

16. HallettTBGarnettGPMupamberiyiZGregsonS 2008 Measuring effectiveness in community randomized trials of HIV prevention. Int J Epidemiol 37 77 87

17. HalloranMEStruchinerCJ 1991 Study designs for dependent happenings. Epidemiology 2 331 338

18. HalloranME 1998 Statistical issues in phase III human immunodeficiency virus vaccine trial design. J R Stat Soc Ser A Stat Soc 161 265 272

19. AlaryMLowndesCMBoilyMC 2003 Community randomized trials for HIV prevention: the past, a lesson for the future? AIDS 17 2661 2663

20. BoilyMCMasseBRDesaiKAlaryMAndersonRM 1999 Some important issues in the planning of phase III HIV vaccine efficacy trials. Vaccine 17 989 1004

21. GarnettGPCousensSHallettTBSteketeeRWalkerN 2011 Mathematical models in the evaluation of health programmes. Lancet 378 515 525

22. EatonJWJohnsonLFSalomonJABärnighausenTBendavidE 2012 HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9 e1001245 doi:10.1371/journal.pmed.1001245

23. BaggaleyRFGarnettGPFergusonNM 2006 Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 3 e124 doi:10.1371/journal.pmed.0030124

24. GranichRMGilksCFDyeCDe CockKMWilliamsBG 2009 Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373 48 57

25. Johnstone-RobertsonSPHargroveJWilliamsBG 2011 Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives? HIV AIDS (Auckl) 3 9 17

26. AlsallaqRBaetenJHughesJAbu-RaddadLCelumC 2012 Modeling the potential impact of a combination prevention based on community-wide HIV testing: KwaZulu Natal, South Africa [abstract]. 19th Conference on Retroviruses and Opportunistic Infections; 5–8 March 2012; Seattle, Washington, US. Available: http://www.retroconference.org/2012b/Abstracts/43187.htm. Accessed 31 May 2012

27. MehtaSDGrayRHAuvertBMosesSKigoziG 2009 Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials. AIDS 23 1557 1564

28. CohenJ 2011 HIV prevention. Halting HIV/AIDS epidemics. Science 334 1338 1340

29. BoilyMCPicklesMVickermanPBuzduganRIsacS 2008 Using mathematical modelling to investigate the plausibility of attributing observed antenatal clinic declines to a female sex worker intervention in Karnataka state, India. AIDS 22 S149 S164

30. VickermanPWattsCDelanySAlaryMReesH 2006 The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis 33 397 405

31. DoddPJGarnettGPHallettTB 2010 Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS 24 729 735

32. BoilyMCLowndesCAlaryM 2002 The impact of HIV epidemic phases on the effectiveness of core group interventions: insights from mathematical models. Sex Transm Infect 78 i78 i90

33. HallettTBSinghKSmithJAWhiteRGAbu-RaddadLJ 2008 Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS ONE 3 e2212 doi:10.1371/journal.pone.0002212

34. GrasslyNCGarnettGPSchwartlanderBGregsonSAndersonRM 2001 The effectiveness of HIV prevention and the epidemiological context. Bull World Health Organ 79 1121 1132

35. GarnettGPAndersonRM 1993 Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philos Trans R Soc Lond B Biol Sci 342 137 159

36. RobinsonNJMulderDAuvertBWhitworthJHayesR 1999 Type of partnership and heterosexual spread of HIV infection in rural Uganda: results from simulation modelling. Int J STD AIDS 10 718 725

37. EatonJWHallettTBGarnettGP 2011 Concurrent sexual partnerships and primary HIV infection: a critical interaction. AIDS Behav 15 687 692

38. BoilyMCAlaryMBaggaleyRF 2012 Neglected issues and hypotheses regarding the impact of sexual concurrency on HIV and sexually transmitted infections. AIDS Behav 16 304 311

39. ChenMIGhaniACEdmundsJ 2008 Mind the gap: the role of time between sex with two consecutive partners on the transmission dynamics of gonorrhea. Sex Transm Dis 35 435 444

40. MishraSVickermanPPicklesMRameshBMWashingtonR 2011 HIV prevention based on the static modes of transmission synthesis for two Indian districts: insights from dynamical modeling [abstract]. 19th Biennial Conference of the International Society for Sexually Transmitted Diseases Research; 10–13 July 2011; Quebec City, Canada. doi:10.1136/sextrans-2011-050108.584

41. HayesRJMoultonLH 2009 Cluster randomized trials. Chapman & Hall/CRC Interdisciplinary Statistics Series Boca Raton (Florida) CRC Press 315

42. LewisFHughesGJRambautAPozniakALeigh BrownAJ 2008 Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med 5 e50 doi:10.1371/journal.pmed.0050050

43. PicklesMFossAMVickermanPDeeringKVermaS 2010 Interim modelling analysis to validate reported increases in condom use and assess HIV infections averted among female sex workers and clients in southern India following a targeted HIV prevention programme. Sex Transm Infect 86 i33 i43

44. HallettTBGregsonSMugurungiOGoneseEGarnettGP 2009 Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. Epidemics 1 108 117

45. BlowerSDowlatabadiH 1994 Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 62 229 243

46. JohnsonLFAlkemaLDorringtonRE 2010 A Bayesian approach to uncertainty analysis of sexually transmitted infection models. Sex Transm Infect 86 169 174

47. DesaiKBoilyMCMasseBAndersonRM 2006 Using transmission dynamics models to validate vaccine efficacy measures prior to conducting HIV vaccine efficacy trials. AbelloJCormodeG Discrete methods in epidemiology Providence (Rhode Island) American Mathematical Society 139 163

48. EmersonSSFlemingTR 2010 Adaptive methods: telling “the rest of the story” J Biopharm Stat 20 1150 1165

49. HsuHSGuptaG 2010 An overview of the FDA draft guidance on adaptive design clinical trials [presentation]. MPCC Seminar Series. Available: http://www.fda.gov/downloads/BiologicsBloodVaccines/…/UCM209179.pdf. Accessed 16 March 2012

50. ChowSCChangM 2008 Adaptive design methods in clinical trials—a review. Orphanet J Rare Dis 3 11

51. GalloPChuang-SteinCDragalinVGaydosBKramsM 2006 Adaptive designs in clinical drug development—an executive summary of the PhRMA Working Group. J Biopharm Stat 16 275 283

52. ZouGYDonnerAKlarN 2005 Group sequential methods for cluster randomization trials with binary outcomes. Clin Trials 2 479 487

53. CookRJLawlessJF 1996 Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics 52 1311 1323

54. Meyer-RathGOverM 2012 HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med 9 e1001247 doi:10.1371/journal.pmed.1001247

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2012 Číslo 7
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Získaná hemofilie - Povědomí o nemoci a její diagnostika

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa